Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
3
×
life sciences
national blog main
boston blog main
boston top stories
drugs
national top stories
new york blog main
san diego blog main
san francisco blog main
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
cannabidiol
cardiomyopathy
dravet syndrome
duchenne muscular dystrophy
dyne therapeutics
epidiolex
facioscapulohumeral muscular dystrophy
fda
fen-phen
fenfluramine
gene therapy
gw pharmaceuticals
inotersen
joshua brumm
kaleido biosciences
lennox-gastaut syndrome
muscular dystrophy
myotonic dystrophy type 1
neuropathy
new york
new york top stories
What
ago
3
×
drug
rare
3
×
approved
battle
data
fda
genetic
medicines
sets
akcea
alnylam
amyloidosis
attr
available
biotechs
cannabis
considering
debilitating
derivative
disease
diseases
dyne
early
epilepsy
expected
experimental
eyes
form
gw
gw’s
having
humans
ipo
ipos
long
marijuana
market
medicine
muscle
Language
unset
Current search:
rare
×
ago
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug